Rein Therapeutics (RNTX) Prepaid Assets (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Prepaid Assets of $90000.0 for Q1 2026, down 89.58% year-over-year from $864000.0 in Q1 2025, and down 89.78% quarter-over-quarter from $881000.0 in Q4 2025.
Rein Therapeutics (RNTX) Prepaid Assets (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Prepaid Assets for 11 consecutive years, with $90000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 89.58% year-over-year to $90000.0; the TTM figure through Mar 2026 stood at $90000.0 (down 89.58% YoY), while the FY2025 annual figure was $881000.0, up 11.24% from the prior year.
- Prepaid Assets slipped to $90000.0 in Q1 2026 per RNTX's latest filing, from $881000.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $1.9 million in Q1 2022 and bottomed at $90000.0 in Q1 2026.
- Historically, Prepaid Assets has averaged $708941.2 across 5 years, with a median of $699000.0 in 2023.
- Annual changes were most pronounced in 2025 — Prepaid Assets soared 476.0% — and 2026, when it slumped 89.58%.
- Rein Therapeutics' Prepaid Assets stood at $606000.0 in 2022, then jumped by 45.54% to $882000.0 in 2023, then decreased by 10.2% to $792000.0 in 2024, then gained by 11.24% to $881000.0 in 2025, then plunged by 89.78% to $90000.0 in 2026.
- Business Quant data shows RNTX's Prepaid Assets at $90000.0 in Q1 2026, $881000.0 in Q4 2025, and $129000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 806,000.00 |
| Mar 31, 2026 | 90,000.00 |
| Dec 31, 2025 | 881,000.00 |
| Sep 30, 2025 | 129,000.00 |
| Jun 30, 2025 | 692,000.00 |
| Mar 31, 2025 | 864,000.00 |
| Dec 31, 2024 | 792,000.00 |
| Sep 30, 2024 | 755,000.00 |
| Jun 30, 2024 | 304,000.00 |
| Mar 31, 2024 | 150,000.00 |
| Dec 31, 2023 | 882,000.00 |
| Sep 30, 2023 | 699,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | 359,000.00 |
| Dec 31, 2022 | 606,000.00 |
| Sep 30, 2022 | 1.55 Mn |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 1.89 Mn |
| Dec 31, 2021 | 2.22 Mn |
| Sep 30, 2021 | 2.17 Mn |